Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics

Journal of Clinical Psychopharmacology

Volumn 34, Issue 1, 2014, Pages 139-142

  Choi, Chang Ik ^a   Bae, Jung Woo ^b   Lee, Yun Jeong ^a,c   Lee, Hye In ^a   Jang, Choon Gon ^a   Lee, Seok Yong ^a  

^a Sungkyunkwan University   (South Korea)

^b Keimyung University   (South Korea)

^c Dankook University   (South Korea)

Author keywords

4 hydroxyatomoxetine; Atomoxetine; CYP2C19; N desmethylatomoxetine; Pharmacokinetics

Indexed keywords

4 HYDROXYATOMOXETINE; ATOMOXETINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DRUG METABOLITE; N DESMETHYLATOMOXETINE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ADRENERGIC UPTAKE INHIBITORS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GENOTYPE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; PHARMACOGENETICS; PHENOLS; PHENOTYPE; PHENYL ETHERS; POLYMORPHISM, GENETIC; PROPYLAMINES; TANDEM MASS SPECTROMETRY;

EID: 84891736662     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182a608a2     Document Type: Article

References (18)

1. Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44:571-590.
2. Sauer JM, Ponsler GD, Mattiuz EL, et al. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos. 2003;31:98-107.
3. Ring BJ, Gillespie JS, Eckstein JA, et al. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos. 2002;30:319-323.
4. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41: 89-295.
5. de Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269:15419-15422.
6. de Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46:594-598.
7. Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41: 913-958.
8. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79:103-113.
9. Li-Wan-Po A, Girard T, Farndon P, et al. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C1917. Br J Clin Pharmacol. 2010;69:222-230.
10. Cui YM, Teng CH, Pan AX, et al. Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D610 allele. Br J Clin Pharmacol. 2007;64:445-449.
11. Matsui A, Azuma J, Witcher JW, et al. Pharmacokinetics, safety, and tolerability of atomoxetine and effect of CYP2D610/10 genotype in healthy Japanese men. J Clin Pharmacol. 2012;52:388-403.
12. Mendoza R, Wan YJ, Poland RE, et al. CYP2D6 polymorphism in a Mexican American population. Clin Pharmacol Ther. 2001;70: 552-560.
13. Johansson I, Lundqvist E, Dahl ML, et al. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics. 1996;6: 351-355.
14. Lundqvist E, Johansson I, Ingelman-Sundberg M. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene. 1999;226: 327-338.
15. Choi CI, Bae JW, Lee HI, et al. Determination of atomoxetine metabolites in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;885-886:103-108.
16. Choi CI, Jang CG, Bae JW, et al. Validation of an analytical LC-MS/MS method in human plasma for the pharmacokinetic study of atomoxetine. J Anal Chem. 2013;68:986-991.
17. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450. 2D6 (;CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6-13.
18. Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116: 496-526.